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This is one of a series of BMJ summaries of new guidelines, which are
based on the best available evidence; they highlight important
recommendations for clinical practice, especially where uncertainty or
controversy exists.
Why read this summary?
Breast cancer is the most common cancer in women and the
second most common cause of death from cancer in women in
the United Kingdom. Each year in the UK more than 12 300
womenand70menwilldiefromadvancedbreastcancerhaving
lived with this condition for an average of two to three years
beforedeath.
1-4Managementofadvancedbreastcancerrequires
the input of a wide range of healthcare professionals, usually
in primary, secondary, and tertiary healthcare settings. Clinical
practice and availability of certain treatments and procedures
are known to vary across the UK. This article summarises the
most recent recommendations from the National Institute for
Health and Clinical Excellence (NICE) on the diagnosis and
treatment of advanced breast cancer.
5
Recommendations
NICErecommendationsarebasedonsystematicreviewsofbest
available evidence. When minimal evidence is available,
recommendations are based on the Guideline Development
Group’s opinion of what constitutes good practice. Evidence
levels for the recommendations are given in italic in square
brackets.
Diagnosis and assessment
Imaging assessment
• Assess the presence and extent of metastases in the bones
of the axial skeleton using bone windows on a computed
tomography (CT) scan or magnetic resonance imaging
(MRI) or using bone scintigraphy.
• Assess proximal limb bones for the risk of pathological
fracture in patients with evidence of bone metastases
elsewhere, using bone scintigraphy and/or plain
radiography. [Based on evidence from small comparative
studies or case series and on the opinion of the Guideline
Development Group]
• Use MRI to assess bony metastases if other imaging is
equivocal for metastatic disease or if more information is
needed (for example, if lytic metastases are encroaching
on the spinal canal).
• Positron emission tomography fused with computed
tomography (PET-CT) should be used to make a new
diagnosisofmetastasesonlyforpatientswithbreastcancer
whose imaging is suspicious but not diagnostic of
metastatic disease. [Based on the opinion of the Guideline
Development Group]
Pathological assessment
• Assess oestrogen receptor and human epidermal growth
factor receptor 2 (HER2) status at the time of disease
recurrence if receptor status was not assessed at the time
of initial diagnosis. In the absence of tumour tissue from
the primary tumour, and if feasible, obtain a biopsy of a
metastasis to assess oestrogen receptor and HER2 status.
[Based on the opinion of the Guideline Development
Group]
• Patients with tumours of known oestrogen receptor status
whose disease recurs should not have a further biopsy just
to reassess that status.
• PatientswithtumoursofknownHER2statuswhosedisease
recursshouldnothaveafurtherbiopsyjusttoreassessthat
status. [Based on limited evidence from observational
studies and on the opinion of the Guideline Development
Group]
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Practice
PRACTICEProviding information and support for
decision making
• Assessthepatient’sindividualpreferencefortheleveland
typeofinformation.Reassessthisascircumstanceschange.
• On the basis of this assessment, offer patients consistent,
relevant information and clear explanations, and provide
opportunities for patients to discuss issues and ask
questions.
• Assess the patient’s individual preference for how much
they wish to be involved in decision making. Reassess this
as circumstances change.
• Be aware of the value of decision aids and the range
available. Ensure that the most appropriate decision aid is
available to the patient. [Based on moderate quality
randomised trials]
Systemic disease modifying therapy
Endocrine therapy
• Offer endocrine therapy as first line treatment for most
patients with oestrogen receptor positive advanced breast
cancer. However, if in such patients the disease is
imminently life threatening or requires early relief of
symptoms resulting from significant visceral organ
involvement, offer chemotherapy as first line treatment
instead, provided that the patients understand and are
prepared to accept the toxicity. [Based on a high quality
systematic review and on the opinion of the Guideline
Development Group]
• Offer an aromatase inhibitor (non-steroidal or steroidal)
to:
-Postmenopausal women with oestrogen receptor positive
breast cancer and no prior history of endocrine therapy
-Postmenopausal women with oestrogen receptor positive
breast cancer previously treated with tamoxifen. [Based
on high quality evidence of clinical and cost effectiveness]
• Offer tamoxifen and ovarian suppression as first line
treatment to premenopausal and perimenopausal women
with oestrogen receptor positive advanced breast cancer
not previously treated with tamoxifen.
• Offer ovarian suppression to premenopausal and
perimenopausal women who have previously been treated
with tamoxifen and who then experience disease
progression. [Based on a moderate quality randomised
controlled trial and a high quality systematic review of
randomised trials]
• Offer tamoxifen as first line treatment to men with
oestrogenreceptorpositiveadvancedbreastcancer.[Based
onlowqualityretrospectivecaseseriesandontheopinion
of the Guideline Development Group]
Chemotherapy
• For most patients who experience disease progression,
offer chemotherapy as a course of treatment with a single
recommended chemotherapy drug. [Based on a limited
randomised trial and on the opinion of the Guideline
Development Group]
• Consider using combination chemotherapy in patients for
whom a greater probability of response is important and
who understand and are likely to tolerate the additional
toxicity. [Based on randomised trial evidence]
• For patients who are not suitable for anthracyclines
(because they are contraindicated or because of prior
anthracyclinetreatmenteitherintheadjuvantormetastatic
setting), offer systemic chemotherapy in the following
sequence:
-First line: single agent docetaxel
-Second line: single agent vinorelbine or capecitabine
-Third line: single agent vinorelbine or capecitabine
(whichever was not used as second line treatment).
[The last bullet point, about patients not suitable for
anthracyclines, is based on a health economic analysis
comparing the cost effectiveness of various sequences of single
agent and combination chemotherapy regimens]
Biological therapy
• For patients receiving treatment with trastuzumab
6 for
advanced breast cancer, discontinue treatment with
trastuzumab at the time of disease progression outside the
central nervous system. Do not discontinue trastuzumab if
disease progression is within the central nervous system
alone. [Based on limited evidence of clinical benefit and a
lack of evidence of cost effectiveness]
Managing complications
Lymphoedema
• Offerallpatientswithlymphoedemacomplexdecongestive
therapy
7 as the first stage of lymphoedema management.
• Consider using multilayer lymphoedema bandaging for
volume reduction as a first treatment option before
compression hosiery. [Based on the opinion of the
Guideline Development Group]
Cancer related fatigue
• Provideinformationaboutandtimelyaccesstoanexercise
programme for all patients experiencing cancer related
fatigue. [Based on a high quality systematic review and
meta-analysis and on the opinion of the Guideline
Development Group]
Uncontrolled local disease
• A breast cancer multidisciplinary team should assess all
patients presenting with uncontrolled local disease and
discuss the therapeutic options for controlling the disease
and relieving symptoms. [Based on poor quality evidence
from small case series, on expert position papers, and on
the opinion of the Guideline Development Group]
Bone metastases
• Consider offering bisphosphonates to patients with a new
diagnosis of bone metastases to prevent skeletal related
events and to reduce pain. [Based on a high quality
systematicreviewandmeta-analysisandmoderatequality
evidence of cost effectiveness]
Brain metastases
• Offer surgery followed by whole brain radiotherapy to
patients who have a single or small number of potentially
resectable brain metastases, a good performance status,
and no or well controlled metastatic disease elsewhere.
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PRACTICE• Offer whole brain radiotherapy to patients for whom
surgery is not appropriate, unless they have a very poor
prognosis. [Based on moderate quality retrospective case
series]
Overcoming barriers
Some of these recommendations have cost implications and/or
will require provision of services not previously provided in
many areas of Britain. Breast cancer has not previously been
listed as an approved indication for PET-CT in the NHS, but
the number of patients needing this procedure in any given
healthcaretrustislikelytobesmall.Provisionoflymphoedema
servicesispatchyaroundtheUK,andtherecommendationsare
likely to require an increase in staff and facilities. Currently
very few areas are likely to provide access to an exercise
programme for cancer related fatigue, so providers will need to
consider how best to provide this. Timeliness of access to
appropriateneurosurgicalservicesmayvary,andimplementing
therecommendationsmayrequirenewprotocolsinsomecancer
networks. The use of trastuzumab beyond disease progression
in HER-2 positive disease varies widely around the UK.
Providers should ensure they have processes that provide
complete transparency about the indication for prescribing
trastuzumab. Processes should be in place to ensure that
trastuzumab is used only in accordance with the indications
agreed by purchasers.
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PRACTICEFurther information on the guidance
Breast cancer is an important condition causing substantial mortality and morbidity in the United Kingdom, with heavy use of healthcare
resources. Introduction of newer and more costly treatments has often proved controversial, with widespread variation in levels of provision
between different areas (so called postcode variation), which has been reduced since the establishment of NICE. Although some of the
more pressing controversies about availability of treatments were managed using the technology appraisal processes (the appraisal process
used by NICE to make binding recommendations about the adoption (or not) of new therapies by the NHS), it is logical to have a single
guideline incorporating recommendations about currently available treatments.
Little is new in this guideline, and the Guideline Development Group believes that it reflects what should be current best practice around the
UK. As outlined in the main text, some cancer centres and units may need to introduce changes to comply with some guideline
recommendations.
The use of trastuzumab at the time of disease progression is thought to vary considerably around the UK. This use is an unlicensed indication,
for which no formal cost effectiveness analysis has been submitted to NICE. The Guideline Development Group feels that in the interests
of equity, trastuzumab beyond progression is not a treatment that should be used in the NHS unless and until a proper appraisal has been
performed.
Methods
The development of this guideline was based on methods outlined by the NICE guidelines manual.
8
Management of advanced breast cancer involves different treatments over time. Limited information was available in the published literature
about comparisons of different sequences of treatments, in particular chemotherapy. In the light of this the development group and health
economists from the London School of Hygiene and Tropical Medicine developed a new health economic model for chemotherapy, to
incorporate the available data from published randomised trials in a manner that permitted a cost effectiveness evaluation. The development
group was aware of the potential limitations of such a model but believed that this model represented a substantial step forward for considering
the “whole of life” treatment of a cancer that will ultimately cause death. It will undoubtedly be refined by others in the future. It was reassuring
that the final output of the model was consistent with what the development group believes to be the most common practices of oncologists
treating breast cancer around the UK.
Future research and remaining uncertainties
The quality of evidence with which to formulate recommendations for managing advanced breast cancer was surprisingly poor. Many
published randomised trials on advanced breast cancer are, in isolation, of an acceptable quality regarding the questions they pose about
the population eligible for the trial. However, it is extremely difficult to put the results of such trials into the context of a whole of life treatment
plan. Substantial further research is required in this area. The quality of health economic information available from most trials is also poor,
and this too needs to be resolved.
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2009;338:b509 doi: 10.1136/bmj.b509 (Published 25 February 2009) Page 4 of 3
PRACTICE